Table 2. Risk of postoperative adverse events in association with myasthenia gravis in the multiple logistic regression models.
| No MG, % | MG, % | OR | (95% CI)a | |
|---|---|---|---|---|
| Postoperative complications | ||||
| Pneumonia | 2.1 | 4.1 | 2.09 | (1.65–2.65) |
| Postoperative bleeding | 0.6 | 0.9 | 1.71 | (1.07–2.72) |
| Septicemia | 3.2 | 4.0 | 1.31 | (1.05–1.64) |
| Pulmonary embolism | 0.1 | 0.1 | 1.18 | (0.36–3.91) |
| Urinary tract infection | 3.5 | 3.5 | 1.02 | (0.80–1.30) |
| Stroke | 2.3 | 1.9 | 0.80 | (0.58–1.11) |
| Deep wound infection | 0.4 | 0.3 | 0.73 | (0.32–1.67) |
| Acute renal failure | 0.9 | 0.5 | 0.58 | (0.32–1.05) |
| Acute myocardial infarction | 0.4 | 0.1 | 0.35 | (0.11–1.12) |
| Any adverse eventsc | 5.3 | 8.3 | 1.70 | (1.44–2.00) |
| 30-day in-hospital mortality | 0.6 | 0.4 | 0.60 | (0.29–1.24) |
| Intensive care unit stay | 13.8 | 36.3 | 5.86 | (5.23–6.57) |
| Length of hospital stay, daysb | 9.1±13.6 | 13.3±16.2 | p<0.0001 | |
| Medical expenditure, US$b | 2060±3922 | 3338±5529 | p<0.0001 | |
CI = confidence interval; ICU = intensive care unit; MG = myasthenia gravis; OR = odds ratio.
aAdjusted for all covariates listed in Table 1.
bMean±SD
cAdverse events include with pneumonia, septicemia, postoperative bleeding.